Voss Capital LP Takes $2.40 Million Position in Kura Oncology, Inc. (NASDAQ:KURA)

Voss Capital LP acquired a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 275,000 shares of the company's stock, valued at approximately $2,395,000. Voss Capital LP owned approximately 0.35% of Kura Oncology as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KURA. Jane Street Group LLC increased its holdings in shares of Kura Oncology by 36.7% in the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company's stock valued at $2,464,000 after acquiring an additional 33,848 shares during the period. Barclays PLC boosted its position in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after purchasing an additional 84,563 shares in the last quarter. Geode Capital Management LLC grew its stake in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after purchasing an additional 41,535 shares during the last quarter. Franklin Resources Inc. raised its holdings in Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock worth $28,687,000 after purchasing an additional 23,113 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock worth $7,997,000 after purchasing an additional 3,092 shares in the last quarter.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company's stock.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $5.90 on Monday. The firm has a market cap of $476.59 million, a PE ratio of -2.50 and a beta of 0.83. The business has a 50-day moving average price of $7.07 and a 200 day moving average price of $10.34. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million. Sell-side analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on KURA shares. UBS Group reduced their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Scotiabank decreased their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.